
CLAIMS


1. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is useful for:

a) administering to the human subject an initial dose of the pharmaceutical composition, wherein said initial dose comprises ~~about~~ 100 to ~~about~~ 600 mg of a compound of Formula (II), wherein said initial dose is administered within from ~~about~~ onset of fever to ~~about~~ 72 hours after~~of~~ fever onset due to dengue infection; and

b) administering to the human subject a plurality of subsequent doses of the pharmaceutical composition, wherein each of said plurality of subsequent doses comprises ~~about~~ 25 to ~~about~~ 300 mg of a compound of Formula (II), wherein said subsequent doses are administered three to four times per day ~~at intervals of from about 6 to about 12 hours~~ until there is an improvement in the infection or between from ~~about~~ 1 day to ~~about~~ 10 days, Formula (II) having the following structure,



(I),



(II),


or a pharmaceutically acceptable salt thereof~~;~~

~~wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.~~

~~2. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for treating a secondary dengue infection in a human subject, wherein the pharmaceutical composition is useful for:~~

~~a) administering to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (I), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and~~

~~b) administering to the human subject a dose of about 25 to about 300 mg of a compound of Formula (I), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,~~




(I),

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.~~

~~3. The use of Claim 1 or Claim 2, wherein the compound of Formula (I), is a compound of Formula (II):~~




(II),

~~or a pharmaceutically acceptable salt thereof.~~

~~4. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is useful for :~~

~~a) administering to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (II), or a pharmaceutical composition comprising a compound of Formula (II), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and~~

~~b) administering to the human subject a dose of about 25 to about 300 mg of a compound of Formula (II), or a pharmaceutical composition comprising a compound of Formula (II), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (II) having the following structure,~~



(II),


~~or a pharmaceutically acceptable salt thereof.~~

~~5. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is in oral form and is useful for:~~

~~a) administering orally to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (I), or a pharmaceutical composition~~

~~comprising a compound of Formula (I), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and~~

~~b) administering orally to the human subject a dose of about 25 to about 300 mg of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,~~



(I),


~~or a pharmaceutically acceptable salt thereof;~~

~~wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.~~

~~6. Use of a compound of Formula (III) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is useful for:~~

~~a) administering to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (III), or a pharmaceutical composition comprising a compound of Formula (III), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and~~

~~b) administering to the human subject a dose of about 25 to about 300 mg of a compound of Formula (III), or a pharmaceutical composition comprising a compound of Formula (III), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (III) having the following structure,~~



(III),

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.~~

~~7. The use according to any one of claims 1 to 6, wherein the pharmaceutical composition is in dose(s) from about 25mg to about 600mg of a compound of Formula (I), the compound of Formula (II) or the compound of Formula (III).~~

~~8. The use of any one of Claims 1-7, wherein the human subject is an adult or a child.~~

~~9. The use of any one of Claims 1-7, wherein the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is converted to castanospermine after administration to a human subject.~~

~~10. The use of any one of Claims 1-9, wherein a steady state Cmin serum or plasma concentration of between about 0.05 and about 2.0 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.~~

~~11. The use of any one of Claims 1-9, wherein a steady state Cmin serum or plasma concentration of between about 1.0 and about 2.0 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.~~

~~12. The use of any one of Claims 1-9, wherein a steady state Cmin serum or plasma concentration of between about 1.0 and about 1.5 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.~~

~~13. The use of any one of Claims 1-9, wherein a steady state Cmin serum or plasma concentration of between about 1.5 and about 2.0 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.~~

~~14. The use of any one of Claims 1-9, wherein a steady state Cmin serum or plasma concentration of between about 1.25 and about 1.75 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.~~

~~15~~2. The use of ~~any one of~~ Claims ~~1-14~~, wherein dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

~~16~~3. The use of ~~any one of~~ Claims ~~1~~ or 2 ~~and 4-15~~, wherein the dengue viral infection is secondary dengue infection.

~~17~~4. The use of any one of Claims 1-~~16~~3, wherein the human subject to be treated is positive prior to treatment for a dengue infection using a NS1 strip assay or quantitative PCR.

~~18. The use of any one of Claims 1-17, wherein the virological log reduction in treated human subjects is at least 50% greater than untreated or placebo-treated groups.~~

~~19. The use of any one of Claims 1-18, wherein administering the pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 0.05 and about 2.0 microgram/mL of castanospermine.~~

~~20. The use of any one of Claims 1-18, wherein administering the pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 1.0 and about 2.0 microgram/mL of castanospermine.~~

~~21. The use of any one of Claims 1-18, wherein administering the pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 1.0 and about 1.5 microgram/mL of castanospermine.~~

~~22. The use of any one of Claims 1-18, wherein administering the pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 1.5 and about 2.0 microgram/mL of castanospermine.~~

~~23. The use of any one of Claims 1-18, wherein administering the pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 1.25 and about 1.75 microgram/mL of castanospermine.~~

~~24. The use of any one of Claims 1-4 and 6-23, wherein the pharmaceutical composition, is for intravenous, oral, rectal, or sublingual administration.~~

~~2~~5. The use of any one of Claims 1-~~2~~4, wherein the human subject is administered an initial dose comprising~~of~~ 150 mg of the compound and subsequent~~a~~ dose~~s~~ comprising~~of~~ 100 mg of the compound are~~is~~ thereafter administered to the human subject ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1~~-day, about 2 days, or about~~ 5 days.

~~2~~6. The use of any one of Claims 1-~~2~~4, wherein the human subject is administered an initial dose comprising~~of~~ 150 mg of the compound and subsequent ~~a~~ dose~~s~~ comprising~~of~~ 150 mg of the compound are~~is~~ thereafter administered to the human subject ~~every 6 hours~~four times per day for ~~about~~ 1~~- day, about 2 days, or about~~ 5 days.

~~2~~7. The use of any one of Claims 1-~~2~~4, wherein the human subject is administered an initial dose comprising~~of~~ 150 mg of the compound and ~~a~~ subsequent dose~~s~~ comprising~~of~~ 150 mg of the compound are~~is~~ thereafter administered to the human subject ~~every 8 hours~~three times per day for ~~about~~ 1~~- day, about 2 days, or about~~ 5 days.

~~28. The use of any one of Claims 1-24, wherein the human subject is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to the human subject every 12 hours for about 1 day, about 2 days, or about 5 days.~~

~~29~~8. The use of any one of Claims 1-~~24~~, wherein the human subject is administered an initial dose comprising~~of~~ 150 mg of the compound and ~~a~~subsequent doses comprising~~of~~ 200 mg of the compound are~~is~~ thereafter administered to the human subject ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1-~~day, about 2 days, or about~~ 5 days.

~~30~~9. The use of any one of Claims 1-~~24~~, wherein the human subject is administered an initial dose comprising~~of~~ 200 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 100 mg of the compound are~~is~~ thereafter administered to the human subject ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1-~~day, about 2 days, or about~~ 5 days.

~~3~~10. The use of any one of Claims 1-~~24~~, wherein the human subject is administered an initial dose comprising~~of~~ 200 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 150 mg of the compound are~~is~~ thereafter administered to the human subject ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1-~~day, about 2 days, or about~~ 5 days.

~~32~~11. The use of any one of Claims 1-~~24~~, wherein the human subject is administered an initial dose comprising~~of~~ 200 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 200 mg of the compound are~~is~~ thereafter administered to the human subject ~~every 6 hours, 8 hours, or 12 hours~~three to four times per day for ~~about~~ 1~~- day, about 2 days, or about~~ 5 days.


~~33. The use of any one of Claims 1-24, wherein the human subject is administered a single or a divided dose of about 25 to about 300 mg of the compound or the pharmaceutical composition, for about between about 5 days to about 10 days.~~

12~~34~~. The use of any one of Claims 1-~~433~~, wherein the human subject is administered a divided initial dose comprising 100 to 600 mg of the compound and subsequent doses comprising ~~of about~~ 25 to ~~about~~ 300 mg of the compound are thereafter administered to the human subject three to four times per day~~, or the pharmaceutical composition,~~ for ~~about~~ between ~~about~~ 5 days to ~~about~~ 10 days.


~~35~~13. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for-:

a) administering to each of the plurality of human subjects an initial dose of the pharmaceutical composition, wherein said initial dose comprises ~~about~~ 100 to ~~about~~ 600 mg of a compound of Formula (II), wherein said initial dose is administered within from ~~about~~ onset of fever to ~~about~~ 72 hours ~~of~~ after fever onset due to dengue infection; and

b) administering to each of the plurality of human subjects a plurality of subsequent doses of the pharmaceutical composition, wherein each of said plurality of -subsequent doses comprises ~~about~~ 25 to ~~about~~ 300 mg of a compound of Formula (II), wherein said subsequent doses are administered three to four times per day ~~at intervals of from about 6 to about 12 hours~~ until there is an improvement in the infection or between from ~~about~~ 1 day to ~~about~~ 10 days, Formula (II) having the following structure,



(I),



(II),


or a pharmaceutically acceptable salt thereof~~;~~

~~wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl~~.

36. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for treating a secondary dengue infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for:

a) administering to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (I), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (I), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,




(I),

or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

37. The use of Claim 35 or Claim 36, wherein the compound of Formula (I), is a compound of Formula (II):




(II),

or a pharmaceutically acceptable salt thereof.

38. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for:

a) administering to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (II), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (II), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (II) having the following structure,




(II),

or a pharmaceutically acceptable salt thereof.

39. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for:

a) administering orally to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (I), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering orally to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (I), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,



(I),


~~or a pharmaceutically acceptable salt thereof;~~

~~wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.~~

~~40. Use of a compound of Formula (III) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for:~~

~~a) administering to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (III), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and~~

~~b) administering to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (III), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (III) having the following structure,~~



(III),

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.~~

~~41. The use according to any one of claims 35 to 40, wherein the pharmaceutical composition is in dose(s) from about 25mg to about 600mg of a compound of Formula (I), the compound of Formula (II) or the compound of Formula (III).~~

~~42. The use of any one of Claims 35-41, wherein the plurality of human subjects includes adults and/or children.~~

~~43. The use of any one of Claims 35-41, wherein the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is converted to castanospermine after administration to each of the plurality of human subjects.~~

~~44. The use of any one of Claims 35-41, wherein an average steady state Cmin serum or plasma concentration of between about 0.05 and about 2.0 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.~~

~~45. The use of any one of Claims 35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.0 and about 2.0 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.~~

~~46. The use of any one of Claims 35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.0 and about 1.5 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.~~

~~47. The use of any one of Claims 35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.5 and about 2.0 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.~~

~~48. The use of any one of Claims 35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.25 and about 1.75 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.~~

1449. The use of ~~any one of~~ Claims 1335-41, wherein dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

1550. The use of ~~any one of~~ Claims 13 or 14~~35 and 38-49~~, wherein the dengue viral infection is secondary dengue infection.

1651. The use of any one of Claims 13-15~~35-50~~, wherein each of the plurality of human subjects to be treated is positive prior to treatment for a dengue infection using a NS1 strip assay or quantitative PCR.

~~52. The use of any one of Claims 35-51, wherein the virological log reduction in treated plurality of human subjects is at least 50% greater than untreated or placebo-treated groups.~~

~~53. The use of any one of Claims 35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 0.05 and about 2.0 microgram/mL of castanospermine.~~

~~54. The use of any one of Claims 35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 1.0 and about 2.0 microgram/mL of castanospermine.~~

~~55. The use of any one of Claims 35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 1.0 and about 1.5 microgram/mL of castanospermine.~~

~~56. The use of any one of Claims 35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 1.5 and about 2.0 microgram/mL of castanospermine.~~

~~57. The use of any one of Claims 35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma~~

~~concentration in the plurality of human subjects of between about 1.25 and about 1.5 microgram/mL of castanospermine.~~

~~58. The use of any one of Claims 35-38 and 40-57, wherein the compound, or the pharmaceutical composition, is administered intravenously, orally, rectally, or sublingually.~~

~~59~~17. The use of any one of Claims 13-16~~35-58~~, wherein each of the plurality of human subjects is administered an initial dose comprising~~of~~ 150 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 100 mg of the compound are~~is~~ thereafter administered to each of the plurality of human subjects ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1 ~~day, about 2 days, or about~~ 5 days.

~~60~~18. The use of any one of Claims 13-16~~35-58~~, wherein each of the plurality of human subjects is administered an initial dose comprising~~of~~ 150 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 150 mg of the compound are~~is~~ thereafter administered to each of the plurality of human subjects ~~every 6 hours~~ four times per day for ~~about~~ 1 ~~day, about 2 days, or about~~ 5 days.

19~~61~~. The use of any one of Claims 13-16~~35-58~~, wherein each of the plurality of human subjects is administered an initial dose comprising~~of~~ 150 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 150 mg of the compound are~~is~~ thereafter administered to each of the plurality of human subjects ~~every 8 hours~~three times per day for ~~about~~ 1 ~~day, about 2 days, or about~~ 5 days.

~~62. The use of any one of Claims 35-58, wherein each of the plurality of human subjects is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to each of the plurality of human subjects every 12 hours for about 1 day, about 2 days, or about 5 days.~~

20~~63~~. The use of any one of Claims ~~35-58~~13-16, wherein each of the plurality of human subjects is administered an initial dose comprising~~of~~ 150 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 200 mg of the compound are~~is~~ thereafter

administered to each of the plurality of human subjects ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1 ~~day, about 2 days, or about~~ 5 days.

~~64~~21. The use of any one of Claims ~~35-58~~13-16, wherein each of the plurality of human subjects is administered an initial dose comprising~~of~~ 200 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 100 mg of the compound are~~is~~ thereafter administered to each of the plurality of human subjects ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1 ~~day, about 2 days, or about~~ 5 days.

~~65~~22. The use of any one of Claims ~~35-58~~13-16, wherein each of the plurality of human subjects is administered an initial dose comprising~~of~~ 200 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 150 mg of the compound are~~is~~ thereafter administered to each of the plurality of human subjects ~~every 6 hours, 8 hours, or 12 hours~~ three to four times per day for ~~about~~ 1 ~~day, about 2 days, or about~~ 5 days.

~~66~~23. The use of any one of Claims ~~35-58~~13-16, wherein each of the plurality of human subjects is administered an initial dose comprising~~of~~ 200 mg of the compound and subsequent~~a~~ doses comprising~~of~~ 200 mg of the compound are~~is~~ thereafter administered to each of the plurality of human subjects ~~every 6 hours, 8 hours, or 12 hours~~three to four times per day for ~~about~~ 1 ~~day, about 2 days, or about 5~~ days.

~~67. The use of any one of Claims 35-58, wherein each of the plurality of human subjects is administered a single or a divided dose of about 25 to about 300 mg of the compound or the pharmaceutical composition, for about between about 5 days to about 10 days.~~

~~68~~24. The use of any one of Claims 13-16~~67~~, wherein each of the plurality of human subjects is administered a divided initial dose comprising 100 to 600 mg of the compound and subsequent doses ~~of about~~ comprising 25 to ~~about~~ 300 mg of the compound~~, or the pharmaceutical composition,~~ are thereafter administered to each of the plurality of human subjects three to four times per day for ~~about~~ between ~~about~~ 5 days to ~~about~~ 10 days.